|Titre :||Prescription opioid analgesic use in France: trends and impact on morbidity-mortality (2018)|
|Auteurs :||C. CHENAF ; J. L. KABORE ; J. DELORME ; B. PEREIRA ; A. MULLIEZ ; M. ZENUT ; N. DELAGE ; D. ARDID ; A. ESCHALIER ; N. AUTHIER|
|Type de document :||Article : Périodique|
|Dans :||European Journal of Pain (Online first 27/07/2018, 2018)|
|Article en page(s) :||11 p. ; doi:10.1002/ejp.1291|
|Discipline :||EPI (Epidémiologie / Epidemiology)|
Thésaurus TOXIBASEMEDICAMENTS ; EVOLUTION ; ANALGESIQUES ; OPIOIDES ; PREVALENCE ; BASE DE DONNEES ; CODEINE ; OPIUM ; MORBIDITE ; MORTALITE ; FENTANYLOIDES ; DOULEUR ; CANCER ; HOSPITALISATION
Background: While data from US and Canada demonstrate an opioid overdose epidemic, very little nation-wide European studies have been published on this topical subject.
Methods: Using a nationally-representative sample of the French Claims database (>700,000 patients), the exhaustive nationwide hospital discharge database, and national mortality registry, all patients dispensed at least one prescription opioid (PO) in 2004-2017 were identified, to describe trends in PO analgesic use, shopping behaviour, opioid-related hospitalizations and deaths. Annual prevalence of PO use and shopping behaviour (>=1 day of overlapping prescriptions from >=2 prescribers, dispensed by >=3 pharmacies) were estimated.
Results: In 2004-2017, the annual prevalence of weak opioid use codeine, tramadol, and opium rose by 150%, 123%, and 244%, respectively (P Conclusions: This study provided a first European approach to a nationwide estimation with complete access to several national registries In 2004-2017 in France, PO use excluding dextropropoxyphene more than doubled. The increase in oxycodone and fentanyl use, and non-trivial increasing trend in opioid-related morbidity-mortality should prompt authorities to closely monitor PO consumption in order to prevent alarming increases in opioid-related morbidity-mortality.
Significance: In 2004-2017, prescription opioid use in France at least doubled and oxycodone use increased particularly, associated with a non-trivial increase in opioid-related morbidity-mortality. Although giving no indication for an "opioid epidemic", these findings call for proper monitoring of opioid use. (This article is protected by copyright. All rights reserved.)
|Domaine :||Autres substances / Other substances|
|Affiliation :||Université Clermont Auvergne, CHU Clermont-Ferrand, Inserm, Neuro-Dol, Service de Pharmacologie médicale, Centres Addictovigilance et Pharmacovigilance, Centre Evaluation et Traitement de la Douleur, Délégation à la Recherche Clinique et à l'Innovation, Clermont-Ferrand, France|